Navigation Links
CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
Date:8/28/2008

CoreValve (www.corevalve.com) announced today that an Australia/New Zealand-focused clinical evaluation of its proprietary percutaneous ReValving System, which features a porcine pericardium valve mounted in a self-expanding frame, was initiated last week.

IRVINE, Calif. (Business Wire EON) August 28, 2008 -- The first four procedures using the CoreValve ReValving System were performed in two days by John Ormiston, M.D., Medical Director at Mercy Hospital in Auckland, New Zealand.

"With the CoreValve ReValving system, a new heart valve can be implanted from a small hole made in the groin, and therefore there is no need for major surgery or an incision in the chest," said Dr. Ormiston. "Patient recovery is much quicker, and the procedure can be performed on patients who are at very high risk, or not candidates, for traditional heart valve surgery. This procedure is truly a revolution in cardiology and is part of the trend toward less-invasive treatment," added Dr. Ormiston. "Currently, percutaneous aortic valve replacement (PAVR) is used for carefully selected high-risk patients only. But if good long-term results are sustained, PAVR may substitute for traditional aortic valve replacement surgery in more patients."

"We are gratified by the continued clinical acceptance of our ReValving technology, the smallest percutaneous system currently available. The extensive clinical experience we have in Europe, where we are the market leader, will greatly facilitate the introduction of our revolutionary technology in the Pacific Rim and other regions throughout the world. Additionally, several scientific presentations regarding our technology and clinical data are scheduled at the upcoming European Society of Cardiology (ESC) meeting in Munich, Germany," said Daniel Lemaitre, CoreValve's President and Chief Executive Officer.

About CoreValve

CoreValve, Inc., is headquartered in Irvine, Calif. Its proprietary ReValving System allows both percutaneous aortic valve replacement (PAVR) and transapical aortic valve replacement (TAVR) and is intended to provide an alternative to open-heart surgery. The ReValving System procedures are performed on the beating heart without cardiac assistance or rapid pacing, and may result in less trauma to the patient. This technology may also offer substantial cost-savings to the healthcare system. The catheter-based technology includes a proprietary framed/self-expanding tissue heart valve that is specifically designed and engineered for transcatheter delivery. For more information about CoreValve, visit the Company's Web site at www.corevalve.com.

(Caution: the CoreValve ReValving System will not be available in the USA for clinical trials or for sale until further notice.)

Read the full story at http://www.prweb.com/releases/corevalve/system/prweb1260384.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
2. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
3. TopoTarget Successfully Buys Back Full Control of Belinostat
4. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
5. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
6. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. Life on Mars pregnancy test successfully launched
9. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
10. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement :  Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries 
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):